Delayed treatment with recombinant Gal-3 after stroke was associated with increased chitinase-3-like protein 3 (Ym1)-positive microgliosis and decreased iNOS expression, indicating that Gal-3 shifted microglia towards anti-inflammatory phenotypes, diminished pro-inflammatory cytokine levels, and conferred neuroprotection (Rahimian et al., 2019b). The gene discussed is LGALS3; the disease is stroke disorder.